KINETA INC (KA)

Company Profile

Kineta, Inc. is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. The company is headquartered in Seattle, Washington and currently employs 11 full-time employees. The company went IPO on 2016-02-11. The firm is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. Its innate immunity development platform aimed at developing human antibodies to address the mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets and research interests includes KVA12123, a monoclonal antibody (mAb), immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. The company is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment. KVA12123 are primarily focused on solid tumors with high levels of VISTA expression.

Company Info

KINETA INC

219 Terry Ave. N., Suite 300

Seattle WASHINGTON

P: 12063780400

Employees: 11

Website: https://kinetabio.com/